Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Frame

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Chronic myeloid leukemia. IntroductionDavid Frame
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
New strategies in controlling drug resistanceDavid Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
New strategies in controlling drug resistance in chronic myeloid leukemiaDavid Frame
Managed Care (Langhorne, Pa.)|January 21, 2010
Alternative dosing schedules for methylation inhibitors in MDS treatmentDavid Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 16, 2006
Chronic myeloid leukemia: standard treatment optionsDavid Frame
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
Introduction: optimizing outcomes through pharmaceutical advances in the treatment of chronic myeloid leukemiaDavid Frame
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2003
Is trastuzumab every three weeks ready for prime time?Melody Cobleigh, David Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Leukemia. Q&A highlightsDavid Frame, Jolynn Sessions, Christopher Fausel
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 13, 2016
Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplantBernard L Marini, Denise Markstrom, David Frame
Pharmacotherapy|January 14, 2003
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatmentSuphat Subongkot, David Frame, William Leslie, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Chronic myeloid leukemia. IntroductionDavid Frame
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
New strategies in controlling drug resistanceDavid Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
New strategies in controlling drug resistance in chronic myeloid leukemiaDavid Frame
Managed Care (Langhorne, Pa.)|January 21, 2010
Alternative dosing schedules for methylation inhibitors in MDS treatmentDavid Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 16, 2006
Chronic myeloid leukemia: standard treatment optionsDavid Frame
Journal of Managed Care Pharmacy : JMCP|November 27, 2007
Introduction: optimizing outcomes through pharmaceutical advances in the treatment of chronic myeloid leukemiaDavid Frame
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2003
Is trastuzumab every three weeks ready for prime time?Melody Cobleigh, David Frame
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 11, 2007
Leukemia. Q&A highlightsDavid Frame, Jolynn Sessions, Christopher Fausel
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 13, 2016
Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplantBernard L Marini, Denise Markstrom, David Frame
Pharmacotherapy|January 14, 2003
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatmentSuphat Subongkot, David Frame, William Leslie, et al.
Pageof 4